| Literature DB >> 33892297 |
Shiv Shankar Gupta1, Ashwani Kumar2, Ravi Shankar3, Upendra Sharma4.
Abstract
The life challenging COVID-19 disease caused by the SARS-CoV-2 virus has greatly impacted smooth survival worldwide since its discovery in December 2019. Currently, it is one of the major threats to humanity. Moreover, any specific drug or vaccine unavailability against COVID-19 forces to discover a new drug on an urgent basis. Viral cycle inhibition could be one possible way to prevent the further genesis of this viral disease, which can be contributed by drug repurposing techniques or screening of small bioactive natural molecules against already validated targets of COVID-19. The main protease (Mpro) responsible for producing functional proteins from polyprotein is an important key step for SARS-CoV-2 virion replication. Natural product or herbal based formulations are an important platform for potential therapeutics and lead compounds in the drug discovery process. Therefore, here we have screened >53,500 bioactive natural molecules from six different natural product databases against Mpro (PDB ID: 6LU7) of COVID-19 through computational study. Further, the top three molecules were subjected to pharmacokinetics evaluation, which is an important factor that reduces the drug failure rate. Moreover, the top three screened molecules (C00014803, C00006660, ANLT0001) were further validated by a molecular dynamics study under a condition similar to the physiological one. Relative binding energy analysis of three lead molecules indicated that C00014803 possess highest binding affinity among all three hits. These extensive studies can be a significant foundation for developing a therapeutic agent against COVID-19 through vet lab studies.Entities:
Keywords: COVID-19; In silico; Main protease; Molecular dynamics; Natural products; Pharmacokinetic parameters
Mesh:
Substances:
Year: 2021 PMID: 33892297 PMCID: PMC8042570 DOI: 10.1016/j.jmgm.2021.107916
Source DB: PubMed Journal: J Mol Graph Model ISSN: 1093-3263 Impact factor: 2.518
Fig. 1Receptor grid generation at active site by specifying internal ligand.
H-bonding of top ranked candidates and reference molecule with main protease (6LU7).
| Compound | Docking score (kcal/mol) | H-bond donor (By ligand to amino acid residue) | H-bond acceptor (By ligand from amino acid residue) |
|---|---|---|---|
| C00014803 (TIPdb) | −12.85 | THR24, THR26, SER46, CYS145, HID163, GLU166, GLN189 | ASN142 |
| C00006660 (TIPdb) | −11.68 | THR26, LEU141, ASN142, THR190 | CYS145 |
| ANLT0001 (Analyticon) | −11.12 | THR26, ASN142, HID163, GLU166 | – |
| Internal Reference (N3) | −8.18 | GLU166, GLN189, THR190 | GLU166 |
Fig. 2Representative top three natural candidates and reference molecule.
Fig. 7Molecular dynamics (RMSD) plots for top ranked ligands a) C00014803; b) C00006660; c) ANLT0001 d) Internal reference (N3) with main protease (6LU7).
Fig. 8Molecular dynamics (RMSF) plots for top ranked ligands a) C00014803; b) C00006660; c) ANLT0001 d) Internal reference (N3) with main protease (6LU7).
Fig. 9Molecular dynamics (radius of gyration i.e. Rg) plots for top ranked ligands (A) C00014803; (B) C00006660; (C) ANLT0001; and (D) reference ligand N3 with main protease.
H-bonding contact of molecular dynamics with significant percentage occupancy of test and reference compounds against residues of nCOV protease during last 50 ns simulation.
| Compounds | Participating amino acid residues (% occupancies) |
|---|---|
| C00014803 | PRO108 (38), GLY109 (31), THR111(26), VAL125 (23) |
| C00006660 | PRO132(38), ASN133(15), ILE136(15), LYS137(15) |
| ANLT0001 | THR111(47), VAL125(23), GLN127(16.6), CYS128(9) |
| N3 (Internal Reference) | ARG131(53), ASN133(45), GLN127(16.6), THR169(28) |
Pharmacokinetic parameters for top ranked candidates.
| Top Ranked | MW | SASA | FOSA | Dipole | QPlogPw | QPlogS | QPlogHERG | QPlogKhsa | Rule of Five | ToxiM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C00014803 | 1155.04 | 1650.33 | 375.99 | 13.46 | 56.44 | −6.05 | −8.03 | −1.99 | 3 | 0.56 | |
| C00006660 | 612.54 | 865.81 | 181.94 | 1.94 | 39.99 | −2.41 | −6.31 | −1.55 | 3 | 0.73 | |
| ANLT0001 | 758.64 | 1006.27 | 257.52 | 13.69 | 48.79 | −1.83 | −6.54 | −2.23 | 3 | 0.68 | |
ADME-T descriptors: MW, molecular weight; SASA, total solvent accessible surface area (SASA) in square angstroms using a probe with a 1.4 Å radius; FOSA, hydrophobic component of the SASA; Dipole’, dipole moment; QPlogPw, predicted water/gas partition coefficient; QPlogS, predicted aqueous solubility; QPlogHERG, Predicted IC50 value for blockage of HERG K+ channels; QPlogKhsa, prediction of binding to human serum albumin.
Relative binding energy profile of top hits along with reference molecule.
| Sr. no | Compounds | Vander Waal’s energy | Electrostatic energy | Polar solvation energy | SASA energy | Binding energy |
|---|---|---|---|---|---|---|
| 1 | C000014803 | −285.12 | −9.83 | 175.33 | −24.01 | −143.63 |
| 2 | C00006660 | −298.23 | −12.91 | 193.85 | −24.04 | −141.33 |
| 3 | ANLT0001 | −190.60 | −7.22 | 107.89 | −12.63 | −102.56 |
| 4 | N3 | −362.22 | −17.84 | 165.88 | −21.66 | −235.84 |
Fig. 32D & 3D interaction diagram of docked C00014803 with main protease (6LU7).
Fig. 42D & 3D interaction diagram of docked C00006660 with main protease (6LU7).
Fig. 52D & 3D interaction diagram of docked ANLT0001 with main protease (6LU7).
Fig. 62D & 3D interaction diagram of docked internal reference (N3) with main protease (6LU7).